Trial Name: GSK-EGF-108916
An Open-Label, Multicenter Study of Lapatinib in Combination with Chemotherapy in Patients with ErbB2 Overexpressing Breast Cancer after Trastuzumab Failure in the Neoadjuvant or Adjuvant Setting
Trial Description:
The study is being done to find out how safe and effective lapatinib is in combination with chemotherapy in female patients with Her2-positive breast cancer who have progressed during or less than or equal to six months after receiving trastuzimab.
Treatment Plan:
Patients will receive lapatinib plus chemotherapy.
Patients:
- Confirmed breast cancer that has relapsed during or less than or equal to six months after completion of trastuzumab, containing therapy in the neoadjuvant or adjuvant setting
- Must have measureable leisions
- Females 18 years or older
- Lab tests, a current physical exam and medical history must meet study specific criteria
This is a brief overview of this clinical trial and only selected eligibility criteria are listed.
If you are interested in receiving more information to see if you are eligible to participate in this study, please contact:
Mercy General Hospital, Rhoda Pineda at (916) 453-4651, or e-mail rpineda@chw.edu
Mercy San Juan Medical Center, Margaret Murphy at (916) 537-5109, or e-mail margaret.murphy2@chw.edu
